

**Boehringer
Ingelheim****RECEIVED
CENTRAL FAX CENTER****JUL 25 2006****Boehringer Ingelheim
Corporation****Telefax**

TO: Commissioner for Patents

DATE: July 25, 2006

Fax Number: 571-273-8300

Total Number of pages: 27(including cover sheet)

Re: Supplemental Response – 9/268

Attached as per Anthony Bottino's request.

Regards,
Linda Boland-Covey

Linda Boland-Covey
Telephone (203) 791-6311
Telefax (203) 798-4408
E-Mail lbolandc@rdg.boehringer-
ingelheim.com

900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368

THIS COMMUNICATION IS INTENDED ONLY FOR THE PERSON OR ENTITY TO WHOM IT IS ADDRESSED (NAMED ABOVE): THE INFORMATION IT CONTAINS MAY BE CONFIDENTIAL AND/OR LEGALLY PRIVILEGED AND PROTECTED IN LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, IT IS HEREBY STIPULATED THAT ANY COPYING, DUPLICATION OR DISTRIBUTION OF THIS DOCUMENT IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE TELEPHONE OR FAX US IMMEDIATELY ON THE NUMBERS SHOWN HERE.

9/268

RECEIVED
CENTRAL FAX CENTER
JUL 25 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : COGAN, D., et al) Art Unit: 1626
U.S. Appln. No. : 10/718,380) Examiner: Shiao, R.T.
Confirmation No. : 9526
U.S. Filing Date : 11/20/2003
Title of Invention : Cytokine Inhibitors
Attny. Docket No. : 9/268

Via fax 571-273-8300
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE

Sir:

In response to the office action dated 2/09/2006, applicants submit herewith a Supplemental Response to the Response dated 06/06/2006, please reconsider the above-identified patent application in view of the following:

Amendments to the claims which are reflected in the Current Listing of Claims which begin on page 2 of this paper.

Remarks/Arguments which begin on page 21 of this paper.